Replies to post #331121 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

All of the published papers relate to filamin A and Alzheimer's (8) were written as the result and under the direction of Cassava.

There is many papers written by independent researchers worldwide regarding sigma 1 and Alzheimer's (111)

That is not a coincidence. Scientist worldwide are seeing the cause and effect relationship for sigma 1 agonists as a treatment and prevention for dementia and nervous system conditions and diseases.

The interesting number of papers published relate to sigma 1 and Alzheimer's (111) compared to the number of papers published relate to filamin A and Alzheimer's (8)

Number of papers published relate to sigma 1 and Alzheimer's (111)

https://pubmed.ncbi.nlm.nih.gov/?term=%22sigma+1%22+%2B+Alzheimer%27s&size=200


Number of papers published relate to filamin A and Alzheimer's (8)

https://pubmed.ncbi.nlm.nih.gov/?term=%22filamin+A%22+%2B+Alzheimer%27s&sort=date&size=200

That being said Cassava Sciences Simufilam MAY prove to have some value for treating Alzheimer's disease, but no where near the value of Anavex Life Sciences's Blarcamesine and/or Anavex 3-71 for the treatment/prevention of Alzheimer's disease and a host of other CNS (Central Nervous System) diseases and/or conditions, etc.

Good luck and GOD bless,